News ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Delayed Nasdaq Stockholm Other stock markets 05:29:17 2024-04-23 am EDT			5-day change	1st Jan Change
2.815 ^SEK	+1.26%		+3.87%	+33.41%

Apr. 16	ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	CI
Feb. 21	ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	Apr. 16	AQ
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	Apr. 16	AQ
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	Apr. 16	CI
ExpreS2ion to present in investor and R&D events in March	Apr. 15	AQ
ExpreS2ion to present in investor and R&D events in March	Feb. 29	AQ
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	Feb. 21	MT
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	Feb. 21	AQ
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	Feb. 08	AQ
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	Jan. 22	AQ
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	Dec. 12	AQ
Pareto Securities publishes research report	Dec. 04	AQ
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	Dec. 01	MT
ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development	Dec. 01	AQ
ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report	Nov. 27	AQ
ExpreS2ion announces financial results for the third quarter 2023	Nov. 16	AQ
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023	Nov. 09	AQ
Background and rationale for the proposed incentive program 2023/2026	23-10-25	AQ
ExpreS2ion Biotech : Bilingual	23-10-24	PU
Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB	23-10-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Summary

Filters